TISSIUM

TISSIUM, Inc. was founded in 2013 and is headquartered in Paris, France. It is a private biotechnology company. The company owns a unique biopolymer platform that addresses the needs of surgical procedures. TISSIUM is developing non-toxic, tissue-adherent, and degradable sealants and adhesives based on this platform to assist in healing wounds caused by minimally invasive surgeries. The company has seven products across three verticals, including nerve repair, hernia, and cardiovascular disease. Each product is designed to uniquely enhance the tissue reconstruction process. Since its establishment, the company has received support from leading healthcare investors such as Omnes Capital, CM-CIC, and CapDecisif Management.